GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - VERASTEM INC

Explicit Guidance:

• Regulatory Submissions: Aiming for a Potential Q2 2026 submission (Q2 potentially of next year) for accelerated approval in second-line PDAC (Target 201 study), contingent on FDA confirmation of the pathway and data maturity.
• Data Readouts & Milestones:
  • Target 201 main cohort enrollment completion expected before end of current year.
  • Target 202 (Lung Cancer) enrollment ongoing; preliminary 900mg data expected to clear accelerated approval bar.
  • Frontline Phase 3 enrollment (Target 301) ongoing; Phase 1 data for frontline GMP combo expected Q2 2026.
  • Randomized Phase 2 (Cetuximab combination vs. monotherapy) in second-line PDAC enrollment to complete mid-year; data readout expected mid-year of next year.
  • Frontline colorectal (CRC) confirmatory study enrollment expected by first half of next year.
  • Phase 1 dose-escalation data for 600mg+ Cetuximab combo and 900mg monotherapy to be disclosed at a future medical meeting, potentially early next year (Q1/Q2).

Business-Segment Outlook:

• G12D Inhibitor (VS-7375): Positioned as "best-in-class" for KRAS G12D-driven cancers (PDAC, CRC, NSCLC).
• PDAC:
  • Indications: Prioritizing accelerated approval in second-line setting (Target 201) due to high unmet need (41% ORR in pre-treated patients, 67% landmark PFS at 6 months).
  • Dosing: Fully characterized 900 mg/day as the optimal dose with identical safety/tolerability to 600 mg; higher dose driven by superior exposure and preclinical models.
  • Frontline: Phase 3 study (Target 301) using a three-armed design combining with Gemcitabine/Nab-paclitaxel (GMP) or Chemotherapy/IO; explicitly excluding Folfirinox to maintain tolerability and leverage single-agent activity.
• Colorectal Cancer (CRC):
  • Strategy: Targeting accelerated approval in third-line/beyond setting where the benchmark ORR is 6% (monotherapy); aiming for >30% ORR.
  • Combination: Unique strategy testing VS-7375 with Cetuximab (anti-EGFR) based on CRISPR screening and preclinical regression; randomized Phase 2 design supports both monotherapy and combination approval claims.
  • Frontline: Confirmatory study starting first half of next year; benchmark comparison against current standard of care (e.g., Fruquintinib monotherapy at 6% ORR).
• Non-Small Cell Lung Cancer (NSCLC):
  • Target: Target D202 study in pre-treated patients; allowing prior taxane exposure (unlike competitors).
  • Efficacy Bar: Targeting >50% ORR by exceeding the current 13–23% standard of care (Docetaxel ± Ramucirumab) at 900mg dose.
  • Brain Metastases: Dedicated cohort (25 patients) to assess blood-brain barrier penetration and reduction of asymptomatic brain mets; a potential differentiator against trimeric inhibitors.
• Commercialization: New CEO (Michael Bailey) starting January 1st to lead commercialization of VS-7375 alongside the approved RAF-MEK/FAK inhibitor (AbMak/Faxinja), which is currently break-even and covers commercial costs.

Market and Competitive Outlook:

• Differentiation: Positioning 900mg dosing and "dual on/off" inhibition profile as superior to competitors (e.g., Zoladix, Insights G12D) which are leaving patients behind in molecular knockdown and durability.
• Combination Landscape: Pursuing "chemo-free" or optimized combination strategies (e.g., PRMT5 inhibitors, Pan-RAS inhibitors) to extend survival beyond the current median of 12 months in PDAC toward 3–5 years.
• Strategic Avoidance: Deliberately avoiding Folfirinox combinations in PDAC frontline to preserve tolerability and single-agent activity, which is deemed the driver of PFS in randomized trials.
• Competitive Gap: Identifying a lack of competitors with "best-in-class" durable disease control (landmark PFS) and single-agent activity in second-line PDAC compared to standard of care (Drexel RAS-SIB at 24% ORR).

Macro / Industry Outlook:

• Regulatory Environment: Anticipating that the FDA will accept "substantial efficacy over standard of care" combined with benefit-risk data (low rates of stomatitis/rash) for accelerated approval in second-line PDAC, where no other competitor is pursuing this specific strategy.
• Market Need: Emphasizing a "call to action" to improve median overall survival in PDAC from current 12 months to 3–5 years through novel combinations.
• Pricing/Dosing: No explicit pricing guidance, but emphasis on 900mg dosing as the global standard for the U.S. program due to optimal exposure.

Strategic Initiatives:

• Leadership Transition: New CEO Michael Bailey commencing January 1st to oversee commercialization; previous CEO Dan Patterson (since 2011) deemed to have delivered to the current stage.
• M&A/Partnerships:
  • GenFleet: Partner for China-based studies (600mg dose); US program running independently with 900mg.
  • PRMT5: Close to announcing a partnership for a PRMT5 inhibitor combination in PDAC to target M-TAP deletion.
  • Pan-RAS: Partnership with Eraska for a "Pan-RAS" inhibitor (switch-two binder) to be combined with VS-7375; preclinical characterization ongoing to potentially lower Pan-RAS dosing and mitigate toxicity (rash/stomatitis).
• Clinical Trial Design: Implementing randomized Phase 2 designs to validate combination contribution without requiring separate control arms for Phase 3, thereby accelerating timelines.
• Capacity/Exposure: Recent capital raise enables "full steam" development across all indications.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Final approval timeline (Q2 2026) is contingent on FDA confirmation of the approval path and data maturity (DOR).
• Safety Profile: While 900mg is tolerable, the primary adverse events remain GI disorders (10–15% Grade 2), which could impact adherence in combination settings.
• Data Robustness: Current Phase 1/2 datasets are small (e.g., 22 patients in PDAC) but consistent; larger confirmatory data is needed for Phase 3 success.
• Competitive Risk: Failure of other G12D inhibitors (e.g., CRYSTAL-10) highlights the difficulty of second-line chemo-combinations, though Veristem argues its combination strategy (chemo-add-on in frontline, chemo-free potential) avoids these pitfalls.
• Toxicity in Combinations: Potential for increased toxicity when combining with other agents (e.g., Pan-RAS, PRMT5) despite preclinical synergy; dosing optimization is critical.

Management Tone on the Future:

• Confidence: High confidence in "best-in-class" status driven by consistent data across tumor types and dose-proportional efficacy.
• Optimism: Describes the upcoming year as "exciting" with "great point" progress toward accelerated approval.
• Hedges: Uses phrases like "fair chance," "potentially," and "aiming towards" regarding regulatory timelines, acknowledging the need for FDA dialogue.
• Urgency: Emphasizes the "call to action" to significantly extend patient survival, driving the aggressive combination strategy.

Miscellaneous:

• Clinical Trial Specifics: Target 201 (2nd line PDAC, monotherapy), Target 202 (NSCLC, pre-treated), Target 301 (Frontline PDAC, 3-arm), and a randomized Phase 2 (2nd line PDAC, monotherapy vs. Cetuximab).
• Geographic Focus: U.S. program optimized for 900mg; China partner (GenFleet) using 600mg.
• Prior Data: October 14th data update highlighted "best in class" potential; 41% ORR in 2nd line PDAC; 67% landmark PFS at 6 months.